By Monica E. Oss This week, we heard some good and bad news about COVID-19. On November 9, Pfizer announced that the vaccine it has developed with German drugmaker BioNTech may be more than 90% effective in preventing the disease among trial volunteers who had no evidence of prior coronavirus infection. The vaccine will be rolled out to health care workers at the end of this year or the beginning of next year. But there are complications. People need two doses of the vaccine for it to be effective, the vaccine has painful temporary side effects, and the vaccines need to be stored at –94 degrees Fahrenheit,…
Content Restricted

This article is reserved for members with an active membership. Please register for a Free Membership to view this resource.

Login to access The OPEN MINDS Circle Library. Not a member? Create your free account now!